03/06/2012
https://www.congress.gov...
"It's interesting sitting up here and listening to testimony, and Dr. Rosenfeld and Dr. Adamis seem like very good folks who have a very strong disagreement, yet the testimony from both of you is very ..."
"Well, if the purpose in doing this is to lower the cost of the drug to the end user or the end payer, and you could get there the same way by just charging 6 percent less or giving a rebate to the phy..."
"It seems like that a competitive market and keeping things competitive, much as has been alluded to in earlier testimony regarding Medicare Part D, would actually drive towards that end anyway, would ..."
"everything we need to do needs to move us towards much, much greater competition and innovation"